摘要
目的:评价CT和血清肿瘤标记物联合检查在卵巢癌诊断与分期中的价值。材料和方法:64例卵巢癌患者,术前行CT与血清CA125、CEA检查,并与手术结果、病理诊断与临床分期相对照分析。结果:CT,CA125,CEA与三者联检对卵巢癌的诊断敏感性分别为89.1%,79.2%,25.0%,98.4%;早期(Ⅰ期)检出率分别为61.5%,53.8%,7.7%,84.6%;临床分期符合率CT为73.4%,CA125为65.6%,三者联检为87.5%。结论:CT与血清肿瘤标记物联检可提高对卵巢癌的诊断敏感性和临床分期符合率。
Purpose： To evaluate the combined application CT and serum tumor markers in diagnosis and staging ovarian carcinoma. Materials and Methods： 64 patients with ovarian carcinoma had CT examination and laboratory detection of serum CA125 and CEA before surgery. Their correlations with the surgery findings, pathologic manifestation and clinical stages were retrospectively analyzed. Results： The sensitivity of CT, CA125 ,CEA and their combination in diagnosing ovarian carcinoma was 89.1%, 79.2%, 25.0% and 98.4%, respectively （ P 〈 0.05 ）. The early detection （ stage I ） was 61.5%, 53.8% , 7.7% and 84.6% , respectively （ P 〈 0.05 ）. The consistency between clinical stage and CT, CA125 and the combination of CT and CA125 was 73.4%, 65.6% , 87.5% respectively （ P 〈 0.05）. Conclusion： The combined application of CT and serum tumor markers in ovarian carcinoma detection could improve the sensitivity of diagnosis and its consistency with clinical staging.
出处
《中国医学影像学杂志》
CSCD
2006年第2期87-91,共5页
Chinese Journal of Medical Imaging
